Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PRCT

PROCEPT BioRobotics Corporation

Healthcare | Medical - Devices

No licensed closing price on file for PRCT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.83

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 12:15 UTC.

What PROCEPT BioRobotics Corporation does

Aqua Surgical is a surgical robotics company that develops and sells the AquaBeam Robotic System and HYDROS Robotic System for minimally invasive urologic surgery, primarily treating benign prostatic hyperplasia, or BPH, a common prostate disease affecting millions of men. The company's Aquablation therapy uses image-guided robotics and heat-free waterjet ablation to remove prostate tissue with personalized treatment planning tailored to each patient's anatomy. The therapy is supported by nine clinical studies and over 150 peer-reviewed publications demonstrating its benefits.

Summarized from PROCEPT BioRobotics Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.83
Debt/equity0.15

Revenue, margins & earnings

FY2021: net loss $60M on revenue $34M$34MFY2021FY2022: net loss $87M on revenue $75M$75MFY2022FY2023: net loss $106M on revenue $136M$136MFY2023FY2024: net loss $91M on revenue $224M$224MFY2024FY2025: net loss $96M on revenue $308M$308MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-05
  • 2026-10-05DirectorStock Option (Right to Buy)Award12,191—
  • 2026-10-05DirectorAward7,727—
  • 2026-09-10EVP, Chief Technology OfficerSale-373$7.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does PROCEPT BioRobotics Corporation do?

Aqua Surgical is a surgical robotics company that develops and sells the AquaBeam Robotic System and HYDROS Robotic System for minimally invasive urologic surgery, primarily treating benign prostatic hyperplasia, or BPH, a common prostate disease affecting millions of men.

When did PRCT last file with the SEC?

PROCEPT BioRobotics Corporation's most recent SEC filing on record is a 8-K filed 2026-06-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:15 UTC. This page is also available as JSON at /api/data?ticker=PRCT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PRCT and 5,000+ tickers.

Create a free account — keep PRCT
For your agent
GET /api/data?ticker=PRCT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt